In Brief This Week: Bruker, Singlera Genomics, Agilent, Ginkgo, Danaher, DiaCarta, DermTech
News items for the week of May 8, 2023.
DiaCarta Nabs FDA Emergency Use Authorization for Monkeypox Test
The laboratory-use QuantiVirus MPXV Test Kit targets two regions of the MPXV genome to detect the virus even if mutations occur in one target region.
DiaCarta to go Public Through SPAC Merger
The firm would join a number of biopharma and diagnostic companies that have used SPACs during the COVID-19 pandemic to tap the public markets.
DiaCarta Gets CE-IVD Mark for SARS CoV-2, Flu A/B Combo Test
The QuantiVirus SARS-CoV-2 Flu A/B Detection Test identifies and distinguishes the three viruses in a single tube using nasopharyngeal swab or saliva samples.
DiaCarta to Explore XNA Clamp Tech for Low-Frequency Mutations Under NIH Collaboration
Working under a two-year cooperative R&D agreement, the firm will explore its platform for cancer and rare disease mutation detection and in situ cancer cell analyses.
Aug 30, 2021
Mar 23, 2020
DiaCarta SARS-CoV-2 Test Kit Receives CE Mark
Feb 12, 2018
DiaCarta Raises $45M in Series B Funding
Feb 21, 2017